At Stanford, the 10-year rate of overall survival for patients having this cytogenetic abnormality is about 55% among those in first complete remission at transplantation, and 20% among those beyond first complete remission.
"Clearly, patients with Philadelphia chromosome–positive ALL are at extraordinary risk and are those who do benefit from transplant," he said.
Dr. Negrin reported that he sits on the data safety monitoring boards for Abbott Pharmaceuticals and Ziopharm, and is a consultant to Genzyme and Baxter. The Oncology Congress is presented by Reed Medical Education. Reed Medical Education and this news organization are owned by Reed Elsevier Inc.